![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Heart disease is a major cause of morbidity and mortality. Cellular therapies hold significant promise for patients with heart disease. Heart-derived progenitor cells are capable of repairing a diseased heart through modulation of growth factor milieu and temporary engraftment leading to endogenous repair. The proof-of-concept CADUCEUS clinical trial using cardiosphere-derived cells has shown evidence of therapeutic cardiac tissue regeneration. Future clinical trials are now being planned to generate additional safety and efficacy data in the hopes of building toward an approved cellular therapy for heart disease.
Financial & competing interests disclosure
E Marbán is a founder and equity holder in Capricor. Capricor provided no funding for the research summarized in this review. Capricor is funding and supporting the execution of the ALLSTAR Phase 2 clinical study mentioned in the Five-year view. E Marbán holds the Mark S Siegel Family Chair of the Cedars-Sinai Medical Center. Relevant research support was provided by the NIH (to E Marbán and to Capricor), the California Institute for Regenerative Medicine (to E Marbán), and the Cedars-Sinai Board of Governors Heart Stem Cell Center (to E Marbán). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.